Efficacy and safety of telavancin in clinical trials: A systematic review and meta-analysis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Polyzos, Konstantinos A ^a   Mavros, Michael N ^a   Vardakas, Konstantinos Z ^a   Makris, Marinos C ^a   Rafailidis, Petros I ^a,b   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELAVANCIN; VANCOMYCIN;

ANEMIA; ARTICLE; CHILL; CLINICAL EFFECTIVENESS; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; GRAM POSITIVE INFECTION; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; HYPOKALEMIA; INFECTION COMPLICATION; INFECTION RATE; INSOMNIA; LEUKOPENIA; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NAUSEA; OUTCOMES RESEARCH; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; SYSTEMATIC REVIEW; TASTE DISORDER; THROMBOCYTE; TREND STUDY; VOMITING;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84865080997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041870     Document Type: Article

References (46)

1. Sakoulas G, Moellering RC Jr, (2008) Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 46 Suppl 5: S360-367.
2. Styers D, Sheehan DJ, Hogan P, Sahm DF, (2006) Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 5: 2.
3. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, et al. (1997) Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40: 135-136.
4. Centers for Disease Control and Prevention (2002) Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 51: 565-567.
5. Centers for Disease Control and Prevention (2002) Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 51: 902.
6. Center for Disease Control and Prevention (2004) Vancomycin-resistant Staphylococcus aureus-New York, 2004. MMWR Morb Mortal Wkly Rep 53: 322-323.
7. Wang G, Hindler JF, Ward KW, Bruckner DA, (2006) Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 44: 3883-3886.
8. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML, (2004) Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 38: 448-451.
9. Vardakas KZ, Mavros MN, Roussos N, Falagas ME, (2012) Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. Mayo Clin Proc 87: 349-363.
10. Stryjewski ME, Chambers HF, (2008) Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46 Suppl 5: S368-377.
11. Eckmann C, Dryden M, (2010) Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res 15: 554-563.
12. Higgins DL, Chang R, Debabov DV, Leung J, Wu T, et al. (2005) Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49: 1127-1134.
13. Chang MH, Kish TD, Fung HB, (2010) Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults. Clin Ther 32: 2160-2185.
14. Pfaller MA, Mendes RE, Sader HS, Jones RN, (2010) Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia. J Antimicrob Chemother 65: 2396-2404.
15. Mendes RE, Sader HS, Farrell DJ, Jones RN, (2011) Update on the telavancin activity tested against European staphylococcal clinical isolates (2009-2010). Diagn Microbiol Infect Dis 71: 93-97.
16. Rubinstein E, Corey GR, Stryjewski ME, Kanafani ZA, (2011) Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia. Expert Opin Pharmacother 12: 2737-2750.
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
18. U.S. Department of Health and Human Services, Food and Drug Administration (2005) Reviewer guidance: conducting a clinical safety review of a new product application and preparing a report on the review. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072974.pdf. Accessed 2012 July 16.
19. Review Manager (RevMan) 5.1 ed: Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
20. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
21. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
22. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
23. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, et al. (2005) Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 40: 1601-1607.
24. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, et al. (2006) Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50: 862-867.
25. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, et al. (2008) Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 46: 1683-1693.
26. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, et al. (2011) Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 52: 31-40.
27. Corey GR, Stryjewski ME, O'Riordan WD, Fowler VG Jr, Ross DP, et al. (2007) ATLAS 1: The first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections. 17th European Congress of Clinical Microbiology and Infectious Diseases ICC, 31 March-04 April, 2007, Munich, Germany.
28. Corey GR, Stryjewski ME, Fowler Jr VG, Teglia O, Hopkins A, et al. (2007) ATLAS 2: A double-blind, randomized, active controlled, multinational Phase 3 study comparing telavancin with vancomycin for the treatment of patients with complicated skin and skin structure infections. 17th European Congress of Clinical Microbiology and Infectious Diseases ICC, 31 March-04 April, 2007, Munich, Germany.
29. Pace JL, Krause K, Johnston D, Debabov D, Wu T, et al. (2003) In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 47: 3602-3604.
30. Leonard SN, Szeto YG, Zolotarev M, Grigoryan IV, (2011) Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 37: 558-561.
31. Pfaller MA, Rhomberg PR, Sader HS, Mendes RE, Jones RN, (2010) Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections. J Chemother 22: 304-311.
32. Logman JF, Stephens J, Heeg B, Haider S, Cappelleri J, et al. (2010) Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin 26: 1565-1578.
33. Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, et al. (2012) Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. J Antimicrob Chemother 67: 1496-1502.
34. Slover CM, Azie N, Barriere S, Lu Q (2011) Telavancin (TLV) for treatment of complicated skin and skin structure infections (cSSSI) in obese patients. 51th ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2011, Chicago, Illinois.
35. Stryjewski ME, Corey GR, Li Y, Barriere S (2011) Post-hoc analysis of efficacy of telavancin in patients with complicated skin and skin structure infections: Applying New FDA Guidance. 51th ICAAC Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2011, Chicago, Illinois.
36. U.S. Department of Health and Human Services, Food and Drug Administration (2010) Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf. Accessed 2012 July 16.
37. European Medicines Agency (2011) Assessment report. Vibativ. International Nonproprietary Name: telavancin. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001240/WC500115363.pdf. Accessed 2012 July 16.
38. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, et al. (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54: 621-629.
39. Falagas ME, Siempos II, Vardakas KZ, (2008) Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 8: 53-66.
40. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, et al. (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52: e18-55.
41. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388-416.
42. Tarchini G, (2011) On a different level: telavancin versus vancomycin for hospital-acquired pneumonia. Clin Infect Dis 52: 1390; author reply 1391-1392.
43. Haque NZ, Zuniga LC, Peyrani P, Reyes K, Lamerato L, et al. (2010) Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 138: 1356-1362.
44. (2008) Telavancin for the Treatment of Complicated Skin and Skin Structure Infections. FDA Briefing Document for Anti-Infective Drugs Advisory Committee Meeting. Food and Drug Administration. Available: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b2-01-FDA.pdf. Accessed 2012 July 16.
45. Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK, (2012) Acute renal insufficiency during telavancin therapy in clinical practice. J Antimicrob Chemother 67: 723-726.
46. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, et al. (2004) Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 44: 689-695.